Shenzhen Kangtai Biological Products Past Earnings Performance
Past criteria checks 2/6
Shenzhen Kangtai Biological Products's earnings have been declining at an average annual rate of -0.3%, while the Biotechs industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 15.3% per year. Shenzhen Kangtai Biological Products's return on equity is 9%, and it has net margins of 24.8%.
Key information
-0.3%
Earnings growth rate
-2.3%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 15.3% |
| Return on equity | 9.0% |
| Net Margin | 24.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Shenzhen Kangtai Biological Products makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3,477 | 861 | 1,507 | 501 |
| 30 Sep 23 | 3,057 | 361 | 1,312 | 579 |
| 30 Jun 23 | 3,060 | 257 | 1,332 | 707 |
| 31 Mar 23 | 3,034 | -201 | 1,326 | 791 |
| 31 Dec 22 | 3,157 | -133 | 1,355 | 802 |
| 30 Sep 22 | 3,840 | 430 | 1,272 | 713 |
| 30 Jun 22 | 4,428 | 1,047 | 1,135 | 569 |
| 31 Mar 22 | 4,247 | 1,512 | 1,013 | 384 |
| 01 Jan 22 | 3,652 | 1,263 | 830 | 354 |
| 30 Sep 21 | 3,218 | 1,282 | 992 | 347 |
| 30 Jun 21 | 2,443 | 756 | 1,061 | 307 |
| 31 Mar 21 | 2,361 | 702 | 1,097 | 299 |
| 31 Dec 20 | 2,261 | 679 | 1,050 | 267 |
| 30 Sep 20 | 1,969 | 577 | 1,002 | 215 |
| 30 Jun 20 | 2,006 | 576 | 1,012 | 212 |
| 31 Mar 20 | 1,779 | 477 | 904 | 206 |
| 31 Dec 19 | 1,943 | 575 | 948 | 198 |
| 30 Sep 19 | 1,911 | 490 | 978 | 219 |
| 30 Jun 19 | 1,761 | 407 | 944 | 201 |
| 31 Mar 19 | 1,955 | 426 | 1,102 | 190 |
| 31 Dec 18 | 2,017 | 436 | 1,156 | 178 |
| 30 Sep 18 | 1,867 | 435 | 1,070 | 118 |
| 30 Jun 18 | 1,756 | 431 | 963 | 133 |
| 31 Mar 18 | 1,418 | 296 | 832 | 100 |
| 31 Dec 17 | 1,161 | 215 | 708 | 85 |
| 30 Sep 17 | 1,006 | 168 | 651 | 51 |
| 30 Jun 17 | 816 | 101 | 582 | 0 |
| 31 Mar 17 | 552 | 52 | 397 | 0 |
| 31 Dec 16 | 552 | 86 | 342 | 0 |
| 30 Sep 16 | 460 | 86 | 378 | 0 |
| 31 Dec 15 | 453 | 63 | 211 | 0 |
| 31 Dec 14 | 303 | 31 | 145 | 0 |
| 31 Dec 13 | 251 | 2 | 169 | 0 |
Quality Earnings: 300601 has high quality earnings.
Growing Profit Margin: 300601 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300601's earnings have declined by 0.3% per year over the past 5 years.
Accelerating Growth: 300601 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 300601 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.6%).
Return on Equity
High ROE: 300601's Return on Equity (9%) is considered low.